Potential Applications of Plant Biotechnology against SARS-CoV-2

Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus responsible for an ongoing human pandemic (COVID-19). There is a massive international effort underway to develop diagnostic reagents, vaccines and antiviral drugs in a bid to slow down the spread of the disease and save lives. One part of that international effort involves the research community working with plants, bringing researchers from all over the world together with commercial enterprises in order to achieve the rapid supply of protein antigens and antibodies for diagnostic kits, and scalable production systems for the emergency manufacturing of vaccines and antiviral drugs. Here we look at some of the ways in which plants can and are being used in the fight against COVID-19.

[1]  E. Rybicki,et al.  Plant molecular farming of virus-like nanoparticles as vaccines and reagents. , 2020, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[2]  Natalie K. Connors,et al.  Bioengineering virus‐like particles as vaccines , 2014, Biotechnology and bioengineering.

[3]  K. Ramessar,et al.  Engineering soya bean seeds as a scalable platform to produce cyanovirin‐N, a non‐ARV microbicide against HIV , 2015, Plant biotechnology journal.

[4]  Yifan Rao,et al.  The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines. , 2020, NPJ vaccines.

[5]  J. Ma,et al.  Transformation of Althaea officinalis L. by Agrobacterium rhizogenes for the production of transgenic roots expressing the anti-HIV microbicide cyanovirin-N , 2013, Transgenic Research.

[6]  Yifan Rao,et al.  The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines , 2020, npj Vaccines.

[7]  L. Pannell,et al.  A potent novel anti-HIV protein from the cultured cyanobacterium Scytonema varium. , 2003, Biochemistry.

[8]  S. Reid,et al.  Development of a novel recombinant encapsidated RNA particle: evaluation as an internal control for diagnostic RT-PCR. , 2007, Journal of virological methods.

[9]  J. C. Kouokam,et al.  Lectins as Promising Therapeutics for the Prevention and Treatment of HIV and Other Potential Coinfections , 2018, BioMed research international.

[10]  Jing Yuan,et al.  Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. , 2020, JAMA.

[11]  Ralph S. Baric,et al.  Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus , 2020, Journal of Virology.

[12]  P. Christou,et al.  Cyanovirin-N produced in rice endosperm offers effective pre-exposure prophylaxis against HIV-1BaL infection in vitro , 2016, Plant Cell Reports.

[13]  K. Whaley,et al.  Emerging antibody products and Nicotiana manufacturing , 2011, Human vaccines.

[14]  Shibo Jiang,et al.  SARS vaccine development. , 2005, Emerging infectious diseases.

[15]  Xinxin Huang,et al.  A brief review of monoclonal antibody technology and its representative applications in immunoassays , 2018, Journal of immunoassay & immunochemistry.

[16]  Zuan-Tao Lin,et al.  Protein Arrays I: Antibody Arrays. , 2017, Methods in molecular biology.

[17]  S. Schillberg,et al.  Transient expression of a tumor-specific single-chain fragment and a chimeric antibody in tobacco leaves. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[18]  K. Musiychuk,et al.  Plant-based rapid production of recombinant subunit hemagglutinin vaccines targeting H1N1 and H5N1 influenza , 2011, Human vaccines.

[19]  Raziel A. Ordóñez,et al.  Unexpected synergistic HIV neutralization by a triple microbicide produced in rice endosperm , 2018, Proceedings of the National Academy of Sciences.

[20]  David C. Montefiori,et al.  Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component , 2009, Proceedings of the National Academy of Sciences.

[21]  M. Moloney,et al.  Plant molecular pharming for the treatment of chronic and infectious diseases. , 2014, Annual review of plant biology.

[22]  Lisa E. Gralinski,et al.  Return of the Coronavirus: 2019-nCoV , 2020, Viruses.

[23]  D. Montefiori,et al.  Activity of and Effect of Subcutaneous Treatment with the Broad-Spectrum Antiviral Lectin Griffithsin in Two Laboratory Rodent Models , 2013, Antimicrobial Agents and Chemotherapy.

[24]  L. Vézina,et al.  The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza. , 2010, Plant biotechnology journal.

[25]  X. Qiu,et al.  The emergence of antibody therapies for Ebola. , 2015, Human antibodies.

[26]  P. Christou,et al.  Cost-effective production of a vaginal protein microbicide to prevent HIV transmission , 2008, Proceedings of the National Academy of Sciences.

[27]  Naveen Vankadari,et al.  Emerging COVID-19 coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26 , 2020, Emerging microbes & infections.

[28]  S. Mittal,et al.  Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses , 2010, Human vaccines.

[29]  R. Twyman,et al.  Molecular farming for new drugs and vaccines , 2005, EMBO reports.

[30]  W. Na,et al.  Ebola outbreak in Western Africa 2014: what is going on with Ebola virus? , 2015, Clinical and experimental vaccine research.

[31]  P. Christou,et al.  Rice endosperm is cost‐effective for the production of recombinant griffithsin with potent activity against HIV , 2016, Plant biotechnology journal.

[32]  R. Twyman,et al.  Pharma-Planta: road testing the developing regulatory guidelines for plant-made pharmaceuticals , 2007, Transgenic Research.

[33]  R. Twyman,et al.  Rice endosperm produces an underglycosylated and potent form of the HIV-neutralizing monoclonal antibody 2G12. , 2016, Plant biotechnology journal.

[34]  R M Twyman,et al.  Can plant biotechnology help break the HIV-malaria link? , 2014, Biotechnology advances.

[35]  S. Perlman,et al.  Severe Acute Respiratory Syndrome Coronaviruses with Mutations in the E Protein Are Attenuated and Promising Vaccine Candidates , 2015, Journal of Virology.

[36]  J. Dubuisson,et al.  Middle East respiratory syndrome coronavirus infection is inhibited by griffithsin , 2016, Antiviral Research.

[37]  H. Perreault,et al.  Mass Spectrometric Characterization of Proteins from the SARS Virus , 2003, Molecular & Cellular Proteomics.

[38]  D. Meyerholz,et al.  Broad-Spectrum In Vitro Activity and In Vivo Efficacy of the Antiviral Protein Griffithsin against Emerging Viruses of the Family Coronaviridae , 2009, Journal of Virology.

[39]  M. Bray,et al.  The cyanobacterial lectin scytovirin displays potent in vitro and in vivo activity against Zaire Ebola virus. , 2014, Antiviral research.

[40]  A. Walls,et al.  Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.

[41]  J. Salinas,et al.  Expression of Immunogenic Glycoprotein S Polypeptides from Transmissible Gastroenteritis Coronavirus in Transgenic Plants☆ , 1998, Virology.

[42]  T. Lehner,et al.  Characterization of a recombinant plant monoclonal secretory antibody and preventive immunotherapy in humans , 1998, Nature Medicine.

[43]  J. Strong,et al.  Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp™ , 2014, Nature.

[44]  J. Ma,et al.  Transgenic plant production of Cyanovirin‐N, an HIV microbicide , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[45]  A. Hiatt,et al.  Production of antibodies in transgenic plants , 1989, Nature.

[46]  Yan Peng,et al.  Effectiveness of convalescent plasma therapy in severe COVID-19 patients , 2020, Proceedings of the National Academy of Sciences.

[47]  C. Pannecouque,et al.  Plant lectins are potent inhibitors of coronaviruses by interfering with two targets in the viral replication cycle , 2007, Antiviral Research.

[48]  Shibo Jiang,et al.  The spike protein of SARS-CoV — a target for vaccine and therapeutic development , 2009, Nature Reviews Microbiology.

[49]  J. Buyel,et al.  Molecular farming - The slope of enlightenment. , 2020, Biotechnology advances.

[50]  T. Mor,et al.  Molecular pharming’s foot in the FDA’s door: Protalix’s trailblazing story , 2015, Biotechnology Letters.

[51]  S. Schillberg,et al.  Critical Analysis of the Commercial Potential of Plants for the Production of Recombinant Proteins , 2019, Front. Plant Sci..

[52]  R. Twyman,et al.  Target product selection - where can Molecular Pharming make the difference? , 2013, Current pharmaceutical design.

[53]  P. Christou,et al.  Seeds as a production system for molecular pharming applications: status and prospects. , 2013, Current pharmaceutical design.

[54]  R. Twyman,et al.  Glyco-Engineering of Plant-Based Expression Systems. , 2018, Advances in biochemical engineering/biotechnology.

[55]  Barry R O'Keefe,et al.  Isolation and Characterization of Griffithsin, a Novel HIV-inactivating Protein, from the Red Alga Griffithsia sp.* , 2005, Journal of Biological Chemistry.

[56]  J. Ma,et al.  Design, expression, and characterization of a multivalent, combination HIV microbicide , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[57]  R. Twyman,et al.  Regulatory approval and a first-in-human phase I clinical trial of a monoclonal antibody produced in transgenic tobacco plants. , 2015, Plant biotechnology journal.

[58]  R. Fischer,et al.  Recombinant antibody 2G12 produced in maize endosperm efficiently neutralizes HIV-1 and contains predominantly single-GlcNAc N-glycans. , 2008, Plant biotechnology journal.

[59]  Paul Christou,et al.  Genetic modification: The production of recombinant pharmaceutical proteins in plants , 2003, Nature Reviews Genetics.